Sera Prognostics (NASDAQ:SERA – Get Free Report) and Nutex Health (NASDAQ:NUTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.
Analyst Recommendations
This is a summary of current ratings and target prices for Sera Prognostics and Nutex Health, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sera Prognostics | 1 | 0 | 1 | 1 | 2.67 |
| Nutex Health | 0 | 2 | 3 | 0 | 2.60 |
Sera Prognostics presently has a consensus target price of $5.50, suggesting a potential upside of 168.29%. Nutex Health has a consensus target price of $243.33, suggesting a potential upside of 35.52%. Given Sera Prognostics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Sera Prognostics is more favorable than Nutex Health.
Insider and Institutional Ownership
Earnings & Valuation
This table compares Sera Prognostics and Nutex Health”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sera Prognostics | $80,000.00 | 1,003.47 | -$31.93 million | ($0.65) | -3.15 |
| Nutex Health | $875.26 million | 1.41 | $70.79 million | $12.94 | 13.88 |
Nutex Health has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Nutex Health, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Sera Prognostics has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Nutex Health has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.
Profitability
This table compares Sera Prognostics and Nutex Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sera Prognostics | -56,385.97% | -41.02% | -30.95% |
| Nutex Health | 10.95% | 23.50% | 10.47% |
Summary
Nutex Health beats Sera Prognostics on 9 of the 15 factors compared between the two stocks.
About Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
About Nutex Health
Nutex Health Inc. operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management. The Real Estate segment owns and owns and leases land and hospital building. The Hospital segment develops and operates a network of micro-hospitals, specialty hospitals and hospital outpatient departments which offers 24/7 care. It also provides operational and managerial services, including management, billing, collections, human resources and recruiting, legal, accounting, and marketing. In addition, the company offers healthcare services, including emergency room care, inpatient care, and behavioral health, as well as onsite imaging, such as CT scan, X-ray, MRI, ultrasound, etc.; certified and accredited laboratories; and onsite inpatient pharmacies. The company was founded in 2011 and is based in Houston, Texas.
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.
